XENE241220C32500
- 0.00
- 0.000.00%
Xenon Pharmaceuticals Newsroom
Xenon Pharmaceuticals Reveals Promising Epilepsy Drug Data
Xenon New Long-Term Azetukalner Data Shows Sustained Monthly Reductions In Seizure Frequency Maintained At 85% At OLE Study Month 36; Approximately 1/3 Patients On Drug For At Least 36-Months Achieved Seizure Freedom For A Period Of 1-Year Or Longer
Express News | Xenon Pharmaceuticals Inc - Ole Data Shows Sustained Monthly Reduction in Seizure Frequency, Consistent Ae Safety Profile
Xenon Pharmaceuticals Named a Best Idea for 2025 at TD Cowen
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Xenon To Present Long-Term Azetukalner Data At AES 2024
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Xenon to Present at Upcoming Investor Conferences
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $56
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
TD Cowen Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $53 to $60
Express News | Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $46 From $49
Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham
Xenon Pharmaceuticals: Strategic Advancements and Promising Clinical Developments Earn a Buy Rating
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript Summary
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript